ËäÈ»Ñо¿ÖصãÊÇÓ볤йÚÏà¹ØµÄÈýÖÖ×î³£¼ûµÄÓ°ÏìÒ»Ñùƽ³£¹¦Ð§µÄÖ¢×´£¬£¬£¬£¬£¬µ«Ò²¿ÉÄܰüÀ¨Ðá¾õºÍζ¾õËðʧ¡¢Ê§Ãß¡¢Î¸³¦µÀÎÊÌâºÍÍ·Í´µÈÖ¢×´¡£¡£¡£µ«ÔÚ´ó´ó¶¼ÇéÐÎÏ£¬£¬£¬£¬£¬ÕâÐ©ÌØÁíÍâÖ¢×´ÓëÖ÷ÒªÖ¢×´Ò»Æð·ºÆð¡£¡£¡£
½Ò¿ªÐ¹ڵIJ¡Àíѧ»úÖÆ
ËÞÖ÷ÃâÒßµ÷ÀíÄÜÁ¦Êǽ¹µã
²î±ðÓÚ¾µäµÄÃâÒßÑ×Ö¢·´Ó¦£¬£¬£¬£¬£¬ÔÚйڲ¡¶¾µÄÇÖÂÔÏ£¬£¬£¬£¬£¬³¤Ð¹ڻ¼ÕßµÄÌåÄÚ·ºÆðÁËÁíÒ»ÖÖ¿¹Ñ×ģʽ£¬£¬£¬£¬£¬¼´½»Ì漫»¯¾ÞÊÉϸ°ûµÄÖ÷µ¼¼²²¡Ä£Ê½£¬£¬£¬£¬£¬Ö±½ÓÓÕ·¢Á˺ã¾ÃÆ£ÀÍ×ÛºÏÕ÷µÄ±¬·¢¡£¡£¡£¸ÃÑо¿ÓÚ2022Äê12ÔÂ2ÈÕ½ÒÏþÔÚCell×Ó¿¯iScienceÉÏ¡£¡£¡£ 
Ñо¿ÕßÌåÏÖ£¬£¬£¬£¬£¬Ïàʶ³¤Ð¹ڵIJ¡Àíѧ»úÖÆÖ»ÊǵÚÒ»²½°ÕÁË£¬£¬£¬£¬£¬ÏÂÒ»²½Ï£Íû¿ÉÒÔΪÕâЩ¡°À§ÓÚ¡±³¤Ð¹ڵϼÕßÌṩ¸ü¶à¸ÄÉÆºÍÖÎÁƵÄÊֶΣ¡¼ä³äÖʸÉϸ°û£¨MSC£¬£¬£¬£¬£¬mesenchymal stem cells£©ÊǸÉϸ°û¼Ò×åµÄÖ÷Òª³ÉÔ±£¬£¬£¬£¬£¬Æä¶ÔÃâÒßϵͳµÄµ÷ÀíÌØÕ÷¾ßÓÐË«ÏòÐÔ£¬£¬£¬£¬£¬ÔÚÃâÒßÁ¦µÍÏÂʱ¼ä£¬£¬£¬£¬£¬Æðµ½ÔöÇ¿ÃâÒßµÄ×÷Ó㻣»£»£»¶ø¶Ô¹ýÇ¿µÄÃâÒß·´Ó¦£¬£¬£¬£¬£¬»á±¬·¢ÒÖÖÆ×÷Óᣡ£¡£¼ä³äÖʸÉϸ°û£¨MSC£©ÒÀ¸½ÆäÇ¿µÄÃâÒßµ÷ÀíÌØÕ÷£¬£¬£¬£¬£¬ÔÚÕâ´ÎÒßÇéµÄÖÎÁÆÖÐҲʩչÁËÖ÷Òª×÷Ó㬣¬£¬£¬£¬¹ØÓÚ·ÀÖÎйڼ°ºóÒÅÖ¢ÓÐÆð¾¢µÄЧӦ¡£¡£¡£
ÃæÁÙí§ÒâºáÐеÄйڲ¡¶¾£¬£¬£¬£¬£¬¶à´Î±»¹úÎñÔºµÈ¹ú¼Ò¼¶¾Û»áÌá¼°µÄ»Ö¸´ÆÚѪ½¬ÁÆ·¨£¬£¬£¬£¬£¬³ÉΪÕü¾ÈÎ£ÖØÖ¢»¼ÕßÉúÃüµÄ¡°ÌØÐ§Ò©¡±£¬£¬£¬£¬£¬»Ö¸´ÆÚѪ½¬ÁÆ·¨£¬£¬£¬£¬£¬½¹µã¾ÍÊÇʹÓÃÆäÖк¬ÓеÄÓ°ÏóµÄ¿¹Ìå»òϸ°û£¬£¬£¬£¬£¬À´¶Ô¿¹²¡¶¾£¬£¬£¬£¬£¬ÒÖÖÆÑ¬È¾£¬£¬£¬£¬£¬µÖ´ï¿µ¸´¡£¡£¡£Ðµķ¢Ã÷£¬£¬£¬£¬£¬Ò²Ö¤ÊµÁËTϸ°ûºÍNKϸ°û¶Ô¿¹²¡¶¾µÄǿʢ·´Ó¦£¬£¬£¬£¬£¬Ô¤Ê¾×źã¾Ã±£»£»£»£»¤ÐÔÃâÒßµÄÉú³¤£¬£¬£¬£¬£¬Ã÷È·ÁËËÞÖ÷ÃâÒß·´Ó¦ÔÚ²¡¶¾É¨³ýÖÐÊÇÒªº¦×÷Óᣡ£¡£Å®ÐÔÏà½ÏÓÚÄÐÐÔÀ´Ëµ£¬£¬£¬£¬£¬¸üÒª±£»£»£»£»¤ºÃ×Ô¼º£¬£¬£¬£¬£¬´Ó¸Éϸ°ûºÍÃâÒßϸ°û˫Ч²ãÃæ¾ÙÐлù´¡ÐÞ¸´£¬£¬£¬£¬£¬´Ó¶øµ÷ÀíÉíÌåÐÔÄÜ£¬£¬£¬£¬£¬Ìá¸ßг´úл£¬£¬£¬£¬£¬ÔöÇ¿ÃâÒßÁ¦£¬£¬£¬£¬£¬Ê¹ÉíÌåÔ½·¢ÄêÇᣬ£¬£¬£¬£¬Ô½·¢¿µ½¡ÓлîÁ¦¡£¡£¡£1¡¢90% of people with long COVID initially had mild symptoms, according to study of 1.2 million people in over 20 countries
2¡¢A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome